News
BMS takes option on Prothena Alzheimer’s drug in $2.2bn deal
Bristol-Myers Squibb has upgraded a long-running alliance with Prothena in Alzheimer’s disease, taking an option on a tau protein-targeting antibody in early-stage clinica
